갑상선암 수술 후 약제 치료: 레보티록신, 칼슘과 비타민 D 맞춤 처방 -최신 가이드라인 중심으로-
Guidelines for the Postoperative Treatment of Thyroid Cancer: Levothyroxine and Calcium/Vitamin D Supplement
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Thyroid hormone replacement is required after surgery for thyroid cancer to manage postoperative hypothyroidism and for thyroid- stimulating hormone (TSH) suppression therapy. However, considering the increased risks of cardiovascular disease and osteoporosis as a result of excessive thyroid hormone administration, it is necessary to maintain the correct dose. This requires prescription strategies tailored to the patient’s individual TSH goals by assessing the risk of recurrence, response to treatment, and risk factors for thyroid hormone therapy. In addition, if hypocalcemia is observed or symptoms of hypocalcemia are detected postoperatively, calcium and vitamin D should be administered to improve the symptoms and maintain serum calcium levels within normal ranges.
Abstract
Thyroid hormone replacement is required after surgery for thyroid cancer to manage postoperative hypothyroidism and for thyroid- stimulating hormone (TSH) suppression therapy. However, considering the increased risks of cardiovascular disease and osteoporosis as a result of excessive thyroid hormone administration, it is necessary to maintain the correct dose. This requires prescription strategies tailored to the patient’s individual TSH goals by assessing the risk of recurrence, response to treatment, and risk factors for thyroid hormone therapy. In addition, if hypocalcemia is observed or symptoms of hypocalcemia are detected postoperatively, calcium and vitamin D should be administered to improve the symptoms and maintain serum calcium levels within normal ranges.
참고문헌 (16)
- 이가희, "2016년 대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안", International Journal of Thyroidology, 9(2), pp.59~126 (2016), 대한갑상선학회
- Haugen BR, "2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26, pp.1~133 (2016)
- Boelaert K, "The association between serum TSH concentration and thyroid cancer", Endocr Relat Cancer, 16, pp.1065~1072 (2009)
- Mazzaferri EL, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 86, pp.1447~1463 (2001)
- McGriff NJ, "Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer", Ann Med, 34, pp.554~564 (2002)
- Pujol P, "Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer", J Clin Endocrinol Metab, 81, pp.4318~4323 (1996)
- Cooper DS, "Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry", Thyroid, 8, pp.737~744 (1998)
- Biondi B, "Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer", Thyroid, 20, pp.135~146 (2010)
- Jo B, "Clinical Thyroidology", pp.520~524 (2014), Korea Medical Book Publishing Company
- Klein Hesselink EN, "Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study", J Clin Oncol, 31, pp.4046~4053 (2013)
- Wang LY, "Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma", Thyroid, 25, pp.300~307 (2015)
- Braverman LE, "Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text" (2013), Lippincott Williams and Wilkins
- Bach-Huynh TG, "Timing of levothyroxine administration affects serum thyrotropin concentration", J Clin Endocrinol Metab, 94, pp.3905~3912 (2009)
- Perez CL, "Serum thyrotropin levels following levothyroxine administration at breakfast", Thyroid, 23, pp.779~784 (2013)
- Udelsman R, "Optimal surgery for papillary thyroid carcinoma", World J Surg, 20, pp.88~93 (1996)
- Bollerslev J, "European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults", Eur J Endocrinol, 173, pp.G1~G20 (2015)